Q2 2019

Filed Aug 14, 2019 · 10-Q · 45 days after period end · 0001493152-19-012595

Q2 2019 · 10-Q

Revenue—

Net Income

-$278.51K

N/M vs Q2 2018

EPS Diluted

-$0.03

N/M vs Q2 2018

Operating Income-$505,264N/M

Operating Cash Flowderived-$80,791N/M

Same quarter

Metric	Q2 2019	Q2 2018	Q2 2017	Q2 2016
Revenue	—	—	$0.00	$0.00
Net Income	-$278.51K	-$671.43K	-$451.09K	-$524.49K
EPS Diluted	-$0.03	-$0.07	-$0.04	-$0.08

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR